The coronavirus pandemic has the world's drugmakers working together to deliver medical solutions and some companies are poised to contribute more than others. With a coronavirus vaccine candidate in late-stage clinical trials and a contract to help manufacture the only COVID-19 antiviral treatment available at the moment, Pfizer (NYSE: PFE) is contributing more than the vast majority of its big pharma peers.
Do Pfizer's contributions to the fight against the COVID-19 pandemic make it a good stock to buy right now? Let's weigh reasons to buy shares of the pharmaceutical giant against the risks.
Image source: Getty Images.